Farmas USA

CLSN

Presenta en el ASCO

http://investor.celsion.com/releaseDetail.cfm?ReleaseID=913045

1. A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors. | 2015 ASCO Annual Meeting Abstracts
... , Boston, MA; Massachusetts General Hospital Cancer Center, Boston, MA; Cellceutix Corporation, Beverly, MA; Cellceutix Corp, Beverly, MA; Cellceutix ...
Terms matched: 1 - URL: /156/AbstView_156_149817.html CTIX

.................................................................................................................

1. Treatment of HIV-associated Kaposi's sarcoma with aldoxorubicin. | 2015 ASCO Annual Meeting Abstracts
... Katie Nguyen; Louisiana State University Health Sciences Center, New Orleans, LA; CytRx Corp, Los Angeles, CA; CytRx Corporation, Los Angeles, CA ...
Terms matched: 1 - URL: /156/AbstView_156_145465.html
2. Longer term cardiac safety of aldoxorubicin. | 2015 ASCO Annual Meeting Abstracts
... , Daniel J. Levitt; Sarcoma Oncology Center, Santa Monica, CA; CytRx Corporation, Los Angeles, CA Abstract Disclosures Abstract: Background: Aldoxorubicin ( ...
Terms matched: 1 - URL: /156/AbstView_156_145435.html
3. Efficacy and safety of adding the retinoid tamibarotene or placebo to paclitaxel/carboplatin for advanced non-small cell lung cancer. | 2015 ASCO Annual Meeting Abstracts
... Scott Wieland; Instituto Nacional de Cancerologia- INCAN, Mexico City, Mexico; CytRx Corporation, Los Angeles, CA; Kansas City Cancer Ctr, Kansas City ...
Terms matched: 1 - URL: /156/AbstView_156_143335.html CYTR

...................................................................................................................

1. Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. | 2015 ASCO Annual Meeting Abstracts
... ; University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Immunomedics, Inc., Morris Plains, NJ; Immunomedics Inc., Morris ...
Terms matched: 1 - URL: /156/AbstView_156_150673.html
2. Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience. | 2015 ASCO Annual Meeting Abstracts
... of Florida, Windermere, FL; Vanderbilt-Ingram Cancer Center, Nashville, TN; Immunomedics Inc., Morris Plains, NJ; Immunomedics, Inc., Morris ...
Terms matched: 1 - URL: /156/AbstView_156_146018.html
3. Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. | 2015 ASCO Annual Meeting Abstracts
... College, New York, NY; University of Florida, Windermere, FL; Immunomedics Inc., Morris Plains, NJ; Immunomedics, Inc., Morris ...
Terms matched: 1 - URL: /156/AbstView_156_148373.html
4. Improvement in imaging of metastatic breast cancer (BC) with a novel pretargeted immuno-PET targeting CEA: First clinical results. | 2015 ASCO Annual Meeting Abstracts
... France; CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France; Immunomedics, Inc.,, Morris Plains, NJ; Immunomedics Inc., ...
Terms matched: 1 - URL: /156/AbstView_156_146928.html
5. A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study. | 2015 ASCO Annual Meeting Abstracts
... Los Angeles, CA; University of Colorado Cancer Center, Aurora, CO; Immunomedics Inc., Morris Plains, NJ; Center for Molecular Medicine and Immunology ...
Terms matched: 1 - URL: /156/AbstView_156_148390.html IMMU

.................................................................................................................

1. Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients. | 2015 ASCO Annual Meeting Abstracts
... Cancer Ctr, Tampa, FL; Moffitt Cancer Center, Tampa, FL; Peregrine Pharmaceuticals, Inc., Tustin, CA Abstract Disclosures Abstract: Background: ...
Terms matched: 1 - URL: /156/AbstView_156_150892.html
2. Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer. | 2015 ASCO Annual Meeting Abstracts
... Hutchins, Bruce Freimark; The University of Texas Southwestern, Dallas, TX; Peregrine Pharmaceuticals, Inc., Tustin, CA; The University of Texas Southwestern ...
Terms matched: 1 - URL: /156/AbstView_156_150815.html
3. A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC). | 2015 ASCO Annual Meeting Abstracts
... Hao Zhu; The University of Texas Southwestern Medical Center, Dallas, TX; Peregrine Pharmaceuticals, Inc., Tustin, CA; Division of Hematology/Oncology ...
Terms matched: 1 - URL: /156/AbstView_156_145009.html PPHM

................................................................................................................

1. TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. | 2015 ASCO Annual Meeting Abstracts
... Jeff Bruce Smaill; Auckland Cancer Society Research Centre, Auckland, New Zealand; Threshold Pharmaceuticals, Inc., South San Francisco, CA; Maurice Wilkins Centre ...
Terms matched: 1 - URL: /156/AbstView_156_153293.html
2. A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma. | 2015 ASCO Annual Meeting Abstracts
... York, NY; Princess Margaret Cancer Centre, Toronto, ON, Canada; Threshold Pharmaceuticals, Inc., South San Francisco, CA Abstract Disclosures Abstract: ...
Terms matched: 1 - URL: /156/AbstView_156_152326.html
3. Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). | 2015 ASCO Annual Meeting Abstracts
... Care, Salinas, CA; Blood Cancer Research Partnership, Boston, MA; Threshold Pharmaceuticals, Inc., South San Francisco, CA Abstract Disclosures Abstract: ...
Terms matched: 1 - URL: /156/AbstView_156_150862.html THLD

......................................................................................................................

1. Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma. | 2015 ASCO Annual Meeting Abstracts
... Category: Central Nervous System Tumors Meeting: 2015 ASCO Annual Meeting Abstract No: 2023 Poster Board Number: Board #12 Citation: J Clin Oncol 33: ...
Terms matched: 1 - URL: /156/AbstView_156_143518.html DMPI

Bueno, 6 de 6....
Todas las de mi cartera tienen presentaciones....
Veamos qué pasa a partir de mañana....

Pues sí, magnífico cierre, con fuerza y solidez... Incluso ha subido un poco en el after que, aunque relativo, siempre gusta que sea verdoso...

Yo de momento, Eleuterio, no las vendo... a ver qué va pasando...

Esta acción me está ilusionando como ADXS...

normal, tu seleccion de farmas es del ramo de la oncologia!!

ese es tu filtro, no? si no recuerdo mal.

aviso a lanzadores de cortos o cazadores de cuchillos

PBYI , PUMA BIOTECHNOLOGY
6-7 Billones $ de Market Cap

bueno, mamporrazo del -25% en after

creo que la fase 3 de cancer de pecho les ha dado un free survival ridiculo

NYMX

Yo hoy vendí un 25%, volví a recomprarlo, y volví a venderlo, con la intención de comprarlo otra vez en el 1.61 más o menos, pero la acción ya no bajó más hasta esa cota. Conservo el 75% del paquete, por ahora no me planteo vender más.

Llevo 5 valores con una compra que hice hoy, normalmente no paso de 4. Mañana no pienso comprar nada por muy bien que esté, no quiero presiones encima por sobrepasarme en renta variable, que con lo de hoy ya me supone un 25% de mi patrimonio, no me gusta pasar del 20% en exposición agresiva.

es decir, 20% en farmas locas y el 80% restante en mierda ibex, supongo, no?